Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 166 Records) |
| Query Trace: Myocardial Infarction and CYP2C19[original query] |
|---|
| CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). American heart journal 2022 8 254 141-148. Kranendonk J, Willems L H, Vijver-Coppen Rj van der, Coenen M, Adang E, Donders R, Zeebregts C J, Deneer Vhm, Reijnen Mmpj, Kramers C, Warlé M |
| Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. Journal of the American Heart Association 2022 6 11 (12): e024709. Madan Mina, Abbott J Dawn, Lennon Ryan, So Derek Y F, MacDougall Andrea M, McLaughlin Mary Ann, Murthy Vishakantha, Saw Jacqueline, Rihal Charanjit, Farkouh Michael E, Pereira Naveen L, Goodman Shaun G, |
| High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials. Journal of clinical pharmacy and therapeutics 2022 4 47 (8): 1112-1121. Sheng Xiao-Yan, An Hui-Jie, He Yong-Yang, Ye Yong-Feng, Zhao Jia-Lan, Li S |
| Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention. European heart journal. Cardiovascular pharmacotherapy 2022 4 8 (8): 806-814. Zhao Xin, Ma Sicong, Kang Yi, Tang Chengchun, Liu Bin, Jiang Hong, Zheng Mingqi, Tang Yu, Sun Hongbin, Liu Yongqiang, Lai Xiaojuan, Gong Yanchun, Li Yongguo, Qi Zizhao, Ren Ling, Li Jing, Li Yi, Han Yali |
| Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation. Clinical pharmacology and therapeutics 2022 4 112 (1): 146-155. Thomas Cameron D, Franchi Francesco, Keeley Ellen C, Rossi Joseph S, Winget Marshall, David Anderson R, Dempsey Alyssa L, Gong Yan, Gower Megan N, Kerensky Richard A, Kulick Natasha, Malave Jean G, McDonough Caitrin W, Mulrenin Ian R, Starostik Petr, Beitelshees Amber L, Johnson Julie A, Stouffer George A, Winterstein Almut G, Angiolillo Dominick J, Lee Craig R, Cavallari Larisa |
| Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis. BMC cardiovascular disorders 2022 3 22 (1): 111. Xie Qiufen, Xiang Qian, Liu Zhiyan, Mu Guangyan, Zhou Shuang, Zhang Zhuo, Ma Lingyue, Gong Yanjun, Jiang Jie, Cui Yim |
| CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. Journal of the American Heart Association 2022 2 11 (4): e024159. Beitelshees Amber L, Thomas Cameron D, Empey Philip E, Stouffer George A, Angiolillo Dominick J, Franchi Francesco, Tuteja Sony, Limdi Nita A, Lee James C, Duarte Julio D, Kreutz Rolf P, Skaar Todd C, Coons James C, Giri Jay, McDonough Caitrin W, Rowland Rachel, Stevenson James M, Thai Thuy, Vesely Mark R, Wellen Jacob T, Johnson Julie A, Winterstein Almut G, Cavallari Larisa H, Lee Craig R, |
| Clopidogrel Use and CYP2C19 Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study. Pharmacogenomics and personalized medicine 2022 15 81-89. Liao Yi-Ju, Hsiao Tzu-Hung, Lin Ching-Heng, Hsu Chun-Sheng, Chang Yen-Lin, Chen Yu-Wei, Hsu Chiann-Yi, Chen Yi-Ming, Wu Ming-F |
| CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study. Frontiers in cardiovascular medicine 2022 12 9 1023004. Yao Haoyi, Qin Kaijie, Liu Yun, Yang Yi, Zhu Jiaxi, Chen Anqing, Wang Zhe, Ye Xiaofeng, Zhou Mi, Li Haiqing, Qiu Jiapei, Zhao Qiang, Zhu Yunpe |
| Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. Cardiovascular drugs and therapy 2022 11 . Mathew Roy O, Sidhu Mandeep S, Rihal Charanjit S, Lennon Ryan, El-Hajjar Mohammed, Yager Neil, Lyubarova Radmila, Abdul-Nour Khaled, Weitz Steven, O'Cochlain D Fearghas, Murthy Vishakantha, Levisay Justin, Marzo Kevin, Graham John, Dzavik Vlad, So Derek, Goodman Shaun, Rosenberg Yves D, Pereira Naveen, Farkouh Michael |
| CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel. Frontiers in cardiovascular medicine 2022 9 994184. Chen Yu-Wei, Liao Yi-Ju, Chang Wei-Chun, Hsiao Tzu-Hung, Lin Ching-Heng, Hsu Chiann-Yi, Liu Tsun-Jui, Lee Wen-Lieng, Chen Yi-Mi |
| CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel. Clinical and translational science 2023 8 . Markus Ramste, Markus Ritvos, Sergei Häyrynen, Johanna I Kiiski, Mikko Niemi, Juha Sinisa |
| The contribution of genotype-guided selection of P2Y inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study. European journal of clinical pharmacology 2023 7 . Yan Wu, Dongbiao Yu, Lei Zhang, Yuting Wu, Bing Shu, Likun Ma, Tianlu S |
| Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC. Cardiovascular interventions 2023 4 16 (7): 829-843. Lee Seung Hun, Jeong Young-Hoon, Hong David, Choi Ki Hong, Lee Joo Myung, Park Taek Kyu, Yang Jeong Hoon, Hahn Joo-Yong, Choi Seung-Hyuck, Gwon Hyeon-Cheol, Jeong Myung Ho, Kim Byeong-Keuk, Joo Hyung Joon, Chang Kiyuk, Park Yongwhi, Ahn Sung Gyun, Suh Jung-Won, Lee Sang Yeub, Cho Jung Rae, Her Ae-Young, Kim Hyo-Soo, Kim Moo Hyun, Lim Do-Sun, Shin Eun-Seok, Song Young Bin, |
| CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome. Research and practice in thrombosis and haemostasis 2023 3 7 (2): 100093. Song Pei-Yuan, Li Mu-Peng, Peng Li-Ming, Chen Xiao-Pi |
| Cytochrome P450 2C19 Polymorphisms and Its Association With Major Adverse Cardiac Events in Post-coronary Intervention Patients on Clopidogrel in the Tertiary Care Center. Cureus 2023 3 15 (2): e34737. Kambhampati Nikhil Teja, Ahamed Hisham, K K Velayudhan, David Sachin, Hakeem Sai Chandra, Pillai Gopalakrishna, Kartha Nivedit |
| Clopidogrel Use in CYP2C19 Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention. Circulation journal : official journal of the Japanese Circulation Society 2023 2 . Sawayama Yuichi, Tomita Yukinori, Kohyama Soji, Higo Yosuke, Kodama Kenji, Asada Kohei, Yagi Noriaki, Fukuyama Megumi, Hayashi Atsushi, Shioyama Wataru, Sakai Hiroshi, Ozawa Tomoya, Isono Tetsuichiro, Hira Daiki, Yamamoto Takashi, Morita Shin-Ya, Nakagawa Yoshihi |
| Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance. JPMA. The Journal of the Pakistan Medical Association 2023 12 73 (12): 2388-2392. Usman Nawaz, Mudassar Noor, Akbar Wahe |
| Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians. The journal of gene medicine 2023 11 e3634. Keshavamurthy Ganapathy Bhat, Ratheesh Kumar Janardhana Pillai, Heemanshu Lodhi, Vivek Singh Guleria, Anil Kumar Abbot, Love Gupta, Garima Rastogi, Anuka Sharma, Zafar Mohammed, Varun Shar |
| CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention (PCI) in the Million Veterans Program. medRxiv : the preprint server for health sciences 2023 11 . Catherine Chanfreau-Coffinier, Kevin A Friede, Mary E Plomondon, Kyung Min Lee, Zhenyu Lu, Julie A Lynch, Scott L DuVall, Jason L Vassy, Stephen W Waldo, John H Cleator, Thomas M Maddox, Daniel J Rader, Themistocles L Assimes, Scott M Damrauer, Philip S Tsao, Kyong-Mi Chang, Deepak Voora, Jay Giri, Sony Tute |
| CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British-South Asians Treated With Clopidogrel. JACC. Advances 2023 10 2 (7): None. Emma F Magavern, Benjamin Jacobs, Helen Warren, Gherardo Finocchiaro, Sarah Finer, David A van Heel, , Damian Smedley, Mark J Caulfie |
| Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Drugs 2024 9 . Dominique P M S M Maas, Loes H Willems, Josephine Kranendonk, Cornelis Kramers, Michiel C War |
| Real-World Implementation of a Genotype-Guided P2Y Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients. JACC. Cardiovascular interventions 2024 9 . Jaouad Azzahhafi, Wout W A van den Broek, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Shabiga Sivanesan, Salahodin Bofarid, Joyce Peper, Daniel M F Claassens, Paul W A Janssen, Ankie M Harmsze, Ronald J Walhout, Melvyn Tjon Joe Gin, Deborah M Nicastia, Jorina Langerveld, Georgios J Vlachojannis, Rutger J van Bommel, Yolande Appelman, Ron H N van Schaik, José P S Henriques, Wouter J Kikkert, Jurriën M Ten Be |
| Impact of proton pump inhibitor use on clinical outcomes in East Asian patients receiving clopidogrel following drug-eluting stent implantation. BMC medicine 2024 8 22 (1): 335. Ju Hyeon Kim, Soon Jun Hong, Jung-Joon Cha, Subin Lim, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Tae Hoon Ahn, Young-Hoon Jeong, Byeong-Keuk Kim, Kiyuk Chang, Yongwhi Park, Young Bin Song, Sung Gyun Ahn, Jung-Won Suh, Sang Yeub Lee, Jung Rae Cho, Ae-Young Her, Hyo-Soo Kim, Moo Hyun Kim, Eun-Seok Shin, Do-Sun L |
| Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes. International journal of molecular sciences 2024 5 25 (10): . Darius ?ereškevi?ius, Vytautas Zabiela, Ali Aldujeli, Vaiva Lesauskait?, Kristina Zubielien?, Vytautas Raškevi?ius, Ieva ?iapien?, Diana Žaliaduonyt?, Agn? Giedraitien?, Vaidotas Žvikas, Valdas Jakštas, Vilius Skipskis, Olivija Dobilien?, Gintar? Šakalyt?, Vacis Tatar?n |
| Prognostic Impact of CYP2C19 Genotypes on Long-Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention. Journal of the American Heart Association 2024 5 13 (10): e032248. Ju Hyeon Kim, Seung-Jun Lee, Jung-Joon Cha, Jae Hyoung Park, Soon Jun Hong, Tae Hoon Ahn, Byeong-Keuk Kim, Kiyuk Chang, Yongwhi Park, Young Bin Song, Sung Gyun Ahn, Jung-Won Suh, Sang Yeub Lee, Jung Rae Cho, Ae-Young Her, Young-Hoon Jeong, Hyo-Soo Kim, Moo Hyun Kim, Eun-Seok Shin, Do-Sun Lim, |
| CYP2C19 Poor Metabolizer Status and High System Inflammation Response Index are Independent Risk Factors for Premature Myocardial Infarction: A Hospital-Based Retrospective Study. International journal of general medicine 2024 11 17 4959-4969. Wendao Han, Nating Xiong, Renkai Zhong, Zhongyi P |
| Genotype-Guided P2Y Inhibitor Monotherapy Within 7 Days of Percutaneous Coronary Intervention in High Bleeding Risk Patients: The CHAMP Trial - A Pilot Study and Safety Assessment. Mayo Clinic proceedings 2024 11 . Brenden S Ingraham, Samuel B Huxley, Conor M Lane, Rajiv Gulati, Bradley R Lewis, Allan S Jaffe, Malcolm R Bell, Amir Lerman, Naveen L Pereira, Ann M Moyer, Linnea M Baudhuin, Charanjit S Rihal, Mandeep Sin |
| Characteristics and predictors of cardiovascular events related to CYP2C19 gene polymorphisms following acute coronary syndrome. European review for medical and pharmacological sciences 2024 10 28 (19): 4347-4354. A V Tran, N T K Nguyen, N T N Pham, B L T Tran, A T Huynh, T H N |
| Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study. Clinical pharmacology and therapeutics 2024 1 . Rika Fukui, Satoshi Noda, Yoshito Ikeda, Yuichi Sawayama, Tomohiro Terada, Yoshihisa Nakagawa, Shin-Ya Mori |
- Page last reviewed:Feb 1, 2024
- Content source: